Background Multiple sclerosis (MS) places a considerable financial burden on the society.
However, data quantifying the contemporary cost burden in France are lacking. Objective …

Introduction: To estimate the value of interventions in multiple sclerosis (MS)–where lifetime
costs and outcomes cannot be observed–outcome data have to be combined with costs …

Background Estimating direct healthcare costs of patients with multiple sclerosis (MS) and
identifying risk factors of high costs including relapse are important drivers of public health …

Background Multiple sclerosis (MS) is a chronic, inflammatory disease of the central nervous
system, commonly diagnosed during young adulthood. The proportion of direct and indirect …

Multiple sclerosis (MS) is one of the 30 chronic conditions specifically listed by the French
healthcare system as a long-term disease (affections de longue durée [ALD]) for which the …

Objectives This study aims to analyse the cost of multiple sclerosis (MS) and its components
in the societal perspective in a cohort of Italian patients treated with disease modifying drugs …

Introduction: To estimate the value of interventions in multiple sclerosis (MS)–where lifetime
costs and outcomes cannot be observed–outcome data have to be combined with costs …

Introduction: In order to estimate the value of interventions in multiple sclerosis (MS)–where
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …

Introduction: In order to estimate the value of interventions in multiple sclerosis (MS)–where
lifetime costs and outcomes cannot be observed–outcome data have to be combined with …

Background: Little is known about changes in the costs of illness (COI) among multiple
sclerosis (MS) patients during recent years. Objectives: To compare the COI among MS …